Piper Jaffrey upgrade (from $8 to $10); here they come...
MannKind (MNKD) AFREZZA May Have Peak Sales of $2 Billion
Piper Jaffray maintained an Overweight rating on MannKind and raised its price target to $10.00 (from $8.00). The change follows Phase 3 Affinity study results. In the view of analyst Ian Somaiya, results support FDA approval of inhaled insulin Afrezza with peak sales more than $2 billion in U.S. and Europe. He also thinks results will allow progress on partner negotiations, though a deal is unlikely before FDA approval, expected in Q2 2014.
All the analysts on the CC congratulated MNKD on meeting the endpoints. As more people get the TRUTH and read the results and transcripts we are going to see more Analyst upgrades and shorty is going to get burned.